Continuing the Success of 2025, Phapros (PEHA) Successfully Records Net Profit Growth of 113% in Quarter 1/2026

JAKARTA, April 21, 2026 - After successfully recording a net profit growth of 109% year-on-year (y-o-y) in 2025 , PT Phapros Tbk (PEHA) has managed to maintain sustainable profitability in 2026. In the first three months of 2026, Phapros once again posted significant net profit growth reaching 112.86% y-o-y.

Phapros' profitability in the first quarter of 2026 was supported by a 10.17% increase in sales to IDR 221.09 billion , compared to IDR 200.67 billion in the same period in 2025. On the other hand, the cost of production or Cost of Goods Sold (COGS) in Q1/2026 only rose by 5.04% , which is lower than the sales growth. As a result, the company's gross profit rose by 16.59% to IDR 103.96 billion , compared to the Q1/2025 period of IDR 89.17 billion.

In addition to maintaining COGS stability, Phapros' operating expenses from January to March 2026 remained relatively stable, only increasing by 7.35% y-o-y. Significant sales growth combined with the ability to maintain COGS and operating expense stability allowed Phapros to record a net profit of IDR 761.49 million in Q1/2026 , an increase of 112.86% compared to the same period the previous year, which saw a loss of IDR 5.92 billion.

Regarding cash position, PEHA also successfully managed its cash flow well. The company's cash flow as of March 31, 2026, was positive at IDR 37.2 billion , an increase of 289.0% compared to the position as of March 31, 2025, which was negative at IDR 19.6 billion. The cash balance at the end of the period also rose by 165% compared to the end of March 2025.

Ida Rahmi Kurniasih, Acting President Director of PT Phapros Tbk, stated that amidst global dynamics full of uncertainty, Phapros was able to maintain good financial performance and achieve net profit. According to her, Phapros consistently implements strategies to optimize all sales channels , maintain product availability stability , and prioritize cost efficiency across all lines. This is done while maintaining high quality standards and compliance with regulations.

"These strategic steps have successfully maintained sustainable profitability. After reversing the condition from a loss in 2024 to a profit in 2025 , we continue to strive to maintain company profitability. This is reflected in the financial performance in Q1/2026 with net profit growth reaching 113%. Addressing the geopolitical impacts causing price increases in materials and costs, we have mitigated risks through purchase contracts since the beginning of the year and continue to monitor developments to stay adaptive. The goal is to secure sales, cost, and net profit targets until the end of the year in accordance with the RKAP," said Ida on Wednesday (April 21, 2026).

Branded Generic Segment Dominant in Quarter 1

Branded Generic Drugs (OGB) became one of the main drivers of sales growth in January-March 2026. OGB sales in Q1/2026 surged 59% to IDR 128.70 billion , compared to IDR 80.88 billion in the same period last year. The contribution of Anti-Tuberculosis drugs for Adults and Children, as well as Blood Supplement Tablets —which are important government programs related to TB, anemia, and stunting—represents PEHA's commitment to improving the health of the Indonesian people.